Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
4.930
+0.410 (9.07%)
At close: Feb 6, 2026, 4:00 PM EST
4.720
-0.210 (-4.26%)
After-hours: Feb 6, 2026, 7:51 PM EST
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
54
Market Cap
318.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | 2.31M | 391.83K | 20.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 113.34M |
| XOMA Royalty | 47.11M |
| X4 Pharmaceuticals | 33.98M |
| Foghorn Therapeutics | 24.52M |
| AC Immune | 5.48M |
IMRX News
- 4 weeks ago - Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data - Seeking Alpha
- 4 weeks ago - Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower - Benzinga
- 4 weeks ago - Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript - Seeking Alpha
- 4 weeks ago - Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - GlobeNewsWire
- 6 weeks ago - Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 - GlobeNewsWire
- 7 weeks ago - Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA - GlobeNewsWire
- 7 weeks ago - Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) - GlobeNewsWire
- 2 months ago - Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire